Merck Healthcare Kgaa, Darmstadt, Germany, An Affiliate Of Merck Kgaa, Darmstadt, Germany
Clinical trials sponsored by Merck Healthcare Kgaa, Darmstadt, Germany, An Affiliate Of Merck Kgaa, Darmstadt, Germany, explained in plain language.
-
New pill could ease muscle weakness in myasthenia gravis patients
Disease control Recruiting nowThis study tests a new oral form of cladribine to see if it improves daily activities and muscle strength in people with generalized myasthenia gravis, a condition causing muscle weakness. About 264 adults will receive either the drug or a placebo, and researchers will track chan…
Phase: PHASE3 • Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany • Aim: Disease control
Last updated May 16, 2026 23:56 UTC
-
New hope for japanese women with infertility: drug combo shows promise in IVF
Disease control Recruiting nowThis study tests a new combination of fertility drugs (follitropin alfa and lutropin alfa) against a standard treatment (hMG) for Japanese women with low levels of two key hormones (LH and FSH) who are undergoing in vitro fertilization (IVF). The goal is to see if the new drug he…
Phase: PHASE3 • Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany • Aim: Disease control
Last updated May 16, 2026 23:53 UTC
-
New hope for rare joint tumor: experimental drug targets stubborn growths
Disease control Recruiting nowThis study tests an experimental drug called pimicotinib in 20 Japanese adults with tenosynovial giant cell tumor (TGCT), a rare, non-cancerous tumor that grows around joints and can cause pain and stiffness. The drug aims to shrink the tumor and improve symptoms. Participants mu…
Phase: PHASE2 • Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany • Aim: Disease control
Last updated May 01, 2026 16:01 UTC
-
Healthy volunteers help test new drug M5542 for first time in humans
Knowledge-focused Recruiting nowThis early-stage study tests a new drug called M5542 in 49 healthy adults. Participants receive a single injection and are monitored for side effects and how the drug moves through the body. The goal is to gather safety information, not to treat any disease.
Phase: PHASE1 • Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany • Aim: Knowledge-focused
Last updated Apr 24, 2026 16:06 UTC